U. QUEENSLAND (AUS) — Scientists have identified signature mutations that drive tumor growth in 30 of the most common cancer types.
The team analyzed more than 7,000 tumors and identified 21 distinct mutational signatures and the cancer types in which they occur.
Professor Sean Grimmond from the University of Queensland’s Institute for Molecular Bioscience says that different mutation-causing processes left genetic “signatures” in cancer cells.
“All cancers are caused by genetic mutations, and in some cases we know the processes driving them, for example, tobacco smoking in lung cancer, however, our understanding of the causes of mutation in most cancers is remarkably limited,” Grimmond says.
“This study allows us to pinpoint the root genetic cause of tumor development in common cancers and, in some cases, to identify the biological process that damages the DNA and gives rise to the cancer.
“For example, we found that a family of enzymes known as APOBECs, which can be activated in response to viruses, is linked to mutations in more than half of the 30 cancer types.”
All of the cancers contained two or more signatures, reflecting the variety of processes that contribute to cancer development.
Professor Andrew Biankin from the Garvan Institute and the University of Glasgow says the findings were exciting because it mean scientists can start to explore the very mechanisms by which genes are damaged for many cancer types.
“It has potentially dramatic implications for early diagnosis, treatment, and particularly prevention in the future,” Biankin says. “If you can understand the chemical processes that are causing the genetic mutations in the first place, it provides a potential avenue for intervention.
“Childhood cancers showed the fewest mutations whereas cancers that were caused by exposure to known carcinogens such as tobacco and UV light had the highest prevalence of mutations.
“Whilst we have good data about the risk of tobacco and UV light, it took many years to discover and here are undoubtedly other risk factors that may never be uncovered without examining the way genes are damaged.
“It is likely we will be able to identify more mutational signatures as more cancers are sequenced and the analysis of these data is further refined.”
“We have identified the majority of the mutational signatures that explain the genetic development and history of cancers in patients,” says Ludmil Alexandrov, first author from the Wellcome Trust Sanger Institute. “We are now beginning to understand the complicated biological processes that occur over time and leave these residual mutational signatures on cancer genomes.”
The findings are published in the journal Nature.
Source: University of Queensland